CSIMarket
 
Mirion Technologies Inc   (MIR)
Other Ticker:  
 
 
Price: $9.8000 $-0.02 -0.204%
Day's High: $9.97 Week Perf: 3.7 %
Day's Low: $ 9.78 30 Day Perf: -7.37 %
Volume (M): 667 52 Wk High: $ 11.78
Volume (M$): $ 6,535 52 Wk Avg: $9.79
Open: $9.92 52 Wk Low: $6.70



 Market Capitalization (Millions $) 1,982
 Shares Outstanding (Millions) 202
 Employees 2,630
 Revenues (TTM) (Millions $) 820
 Net Income (TTM) (Millions $) -66
 Cash Flow (TTM) (Millions $) -686
 Capital Exp. (TTM) (Millions $) 33

Mirion Technologies Inc
Mirion delivers solutions, services, and software that enable our clients to safely harness the power of ionizing radiation for the benefit of humanity. Our solutions are essential in the medical, nuclear energy, and military industries, as well as in labs, scientific research, analysis, and space exploration. Several of our markets are defined by the necessity to fulfill stringent regulatory standards, design qualities, and operational constraints. Throughout our history, we have effectively used the power of our ionizing radiation knowledge to promote continuous innovation and increase the commercial applications of our core technical skills. We serve the Americas, Europe, Africa, the Middle East, and Asia Pacific areas with 13 locations in 13 countries.
We have two reportable business segments: Medical and Industrial. Our Medical segment supports applications in medical diagnostics, cancer treatment, practitioner safety and rehabilitation. Our products in these fields are focused on enhancing the effectiveness and safety of life-saving procedures. Our Industrial segment is focused on addressing critical radiation safety, measurement and analysis applications across nuclear energy, defense, laboratories and research and other industrial markets. Products and solutions of our Medical segment and of our Industrial segment include: dosimetry services (environmental radiation monitoring dose of records services), cancer diagnostics and therapy quality assurance, or "QA", nuclear medicine, dosimeters (wearable devices that measure exposure to ionizing radiation), contamination and clearance monitors, detection and identification instruments, radiation monitoring systems, electrical penetrations, reactor instrumentation and control equipment and systems, medical and industrial imaging systems and related accessories, software and services, alpha spectroscopy instruments (instruments that quantify and identify alpha-emitting nuclides), alpha/beta counting instruments (instruments for quantification of alpha and beta radiation) and gamma spectroscopy detector systems (instruments for qualification and quantification of gamma emitting nuclides) and software (related software to support our product and solution offerings).
For more than 60 years, we and our predecessor companies have delivered products and services that enable our customer to harness ionizing radiation for applications that benefit the health, safety, vitality and technological progress of humanity. We believe the breadth and proven performance of our solutions support our longstanding strategic customer partnerships across diverse end markets. Our products, software and services have been sold directly and indirectly to a variety of end-use customers, including, medical service providers, the vast majority of the U.S. nuclear power producers and the addressable global installed base of active nuclear power reactors, many of the leading nuclear reactor design firms, universities, numerous international government and supranational agencies, 19 of the 28 NATO militaries, national laboratories, environmental laboratories, research institutes and industrial companies.
Our broad product and services portfolio of medical, search, measurement, scientific analysis and reactor safety and control systems are supported by our engineering and research and development organization of 356 scientists, engineers and technicians, who represented approximately 14% of our workforce as of December 31, 2021. We possess numerous product qualifications, trade secrets and patents that support our market position and our ability to deliver next generation products and services. In addition, we maintain design, manufacturing and sales capabilities across 12 countries in America, Europe and Asia, enabling us to capitalize on growth opportunities, including the ongoing growth in spending for medical, defense and homeland security and the ongoing growth for nuclear power.
Our financial performance is driven by the replacement of products and the recurring provision of services into our core end markets, as well as the construction of new facilities like nuclear power plants, or NPPs, globally.

Medical
Our Medical segment encompasses five major product categories focused on supporting applications in medical diagnostics, cancer treatment, practitioner safety and rehabilitation. Our products in these fields are focused on enhancing the effectiveness and safety of life-saving procedures.
Cancer Diagnostics and Therapeutics QA: we provide integrated solutions for independent quality management in the diagnosis and treatment of cancer. Our suite of patient, machine, and diagnostic QA solutions are relied on in the field to mitigate errors, reduce inefficiencies, validate technologies/techniques and elevate the quality of clinical care. Our products include arrays for machine and patient QA solutions, software platforms for centralized analysis and data storage, lasers to align Linacs to patient or QA devices, and phantoms (devices to simulate the imaging and radiation dose absorption characteristics of human tissue) for machine and patient QA.
Nuclear Medicine and Medical Imaging: we provide solutions for patient dosing, imaging, diagnosis and radiopharma production and handling as well as specialized medical imaging tables and accessories that support imaging techniques and procedures. Our products include our range of dose calibrators, radiation shielding, phantoms for quality assurance, phantoms, thyroid uptake systems, lung scan ventilation systems, ultrasound tables, C-Arm tables and accessories.
Medical Imaging: we provide specialized medical imaging tables and accessories that support imaging techniques and procedures, including ultrasound tables, C-Arm tables and accessories.
Dosimetry Services: our product offering is an information service, which provides environmental radiation monitoring services, as well as an official dose of record to employers and occupationally exposed employees, enhancing the effectiveness and efficiency of radiation safety programs at practitioner sites. Key product lines include the innovative Instadose dosimetry platform, optically stimulated luminescence, or OSL, dosimeters, and our range of eye, finger, and extremity dosimeters that integrate with our Dose Central data platform.
Rehabilitation: we provide neuromuscular assessment and rehabilitation technology solutions. Our products are used to manage and rehabilitate the physical and performance deficits that cause functional limitations. Our technology safely progresses a patient through the physical rehabilitation progress. Our rehabilitation products are used in patients throughout the continuum of life ' from injuries requiring sports medicine and orthopedics to interventions for our aging population such as fall prevention and all ages with neurologic conditions due to strokes, Parkinson's Disease, spinal cord and traumatic brain injury. Our products include isokinetic testing and rehabilitation systems, balance assessment and rehabilitation, specialized gait training treadmills, body weight support training systems and upper, lower and total body ergometers.
Industrial
Our Industrial segment is focused on addressing critical radiation safety, measurement and analysis applications across defense, nuclear energy, laboratories and research and other industrial markets.
Reactor Safety and Control Systems: we provide radiation monitoring systems and reactor instrumentation and control systems that ensure the safe operation of nuclear reactors and other nuclear fuel cycle facilities. Product lines include, but are not limited to, a range of areas such as effluent release and operational process monitors, as well as in-core and ex-core detector systems, electrical penetrations, boron meters, and nuclear containment seals. Select product categories include:

Radiation Monitoring Systems: sensors, displays, control electronics and software used for barrier leak control, effluent release monitoring, operational process monitoring and 'post event' monitoring in NPPs, nuclear fuel cycle industry, research reactors and laboratories, military reactors and installations.
Reactor Instrumentation and Control Equipment and Systems: sensors, cables and electronics designed to monitor radiation and temperature within a reactor core and in surrounding areas.
Neutron Flux Measurement Systems: sensors, displays, control electronics and software used to control the core of a reactor in NPPs, research reactors, and military reactors.


   Company Address: 1218 Menlo Drive Atlanta 30318 GA
   Company Phone Number: 432-2744   Stock Exchange / Ticker: NYSE MIR


Customers Net Income grew by MIR's Customers Net Profit Margin grew to

21.64 %

10.6 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
TMO   -0.57%    
AME        2% 
FTV        3.06% 
KVHI        2.91% 
TDY        0.76% 
• View Complete Report
   



Dividend

Mirion Announces Strong Second Quarter Results and Expands Market Presence in Radiation Detection Industry

Published Fri, Aug 2 2024 12:06 AM UTC


Atlanta-based Mirion, a leading provider of radiation detection, measurement, analysis, and monitoring solutions, has recently released its second quarter results for 2024. The company reported that its performance was in line with expectations, demonstrating steady top-line growth and impressive expansion in Adjusted EBITDA margin. Mirion's Chief Executive Officer, Tho...

Dividend

Mirion's Steady Growth and Strong Profitability Drive Positive Market Response

Published Thu, Aug 1 2024 10:57 PM UTC

Mirion, a leading provider of radiation detection solutions, has released its financial results for the second quarter of 2024, along with an update on their full-year guidance. The CEO, Thomas Logan, expressed satisfaction with the results, stating that both segments of the company achieved steady top-line growth and significant expansion in Adjusted EBITDA margin. These po...

Mirion Technologies Inc

Mirion Technologies Inc. Struggles with Rising Revenue but Still Faces Deficit in Q1 2024

Mirion Technologies Inc, a leading provider of radiation detection and measurement solutions, has been facing significant challenges in its financial performance. The company reported a loss of $-0.13 per share in the first quarter of 2024, compared to a loss of $-0.22 per share in the same period last year. This is a worrisome trend as it indicates a deterioration in the company's profitability. Additionally, Mirion Technologies saw a growth shortfall of $-0.07 per share from the previous financial reporting period, suggesting a decline in its financial health.
While the company experienced a revenue growth of 5.491% to $192.10 million in the first quarter of 2024, it is important to note that this growth is lower than the industry average. The Scientific & Technical Instruments sector, in which Mirion Technologies operates, experienced a contraction of -2.99% in its top-line revenue. This indicates that Mirion Technologies is not performing as well as its peers in the industry.

Mirion Technologies Inc

Mirion Technologies Inc. Shows Improvement in Revenue Growth Despite Fourth Quarter Deficit

Mirion Technologies Inc, a global provider of radiation detection, measurement, analysis, and monitoring solutions, recently announced its financial results for the October to December 31, 2023 fiscal timeframe. Despite reporting a loss of $-0.07 per share, which is an improvement from the $-0.53 loss per share from a year ago, the company saw an increase in revenue by 5.782% to $230.50 million. This growth is a positive sign for the company's performance in the market.
Additionally, Mirion Technologies Inc reported a net deficit of $-14.500 million for the same period, a significant improvement from the $-159.700 million deficit in the previous year. The company also experienced a decrease in inventories to $144.1 million, indicating a strong demand for its products. The accounts receivable increased to $172.3 million, a positive signal for the company's financial health.

Contract

Revolutionizing Energy: Mirion Technologies Collaborates with TerraPower for World's First Fast-Spectrum Salt Reactor

Published Thu, Nov 16 2023 1:00 PM UTC



In a significant development towards combating climate change and supporting clean energy, Mirion Technologies, a leading provider of advanced radiation safety solutions, has signed an agreement with nuclear innovation company TerraPower. The collaboration aims to design and fabricate crucial components for the Molten Chloride Reactor Experiment (MCRE), the world's...







Mirion Technologies Inc's Segments

  Mirion Technologies Inc Outlook

On April 30 2024 the Mirion Technologies Inc provided following guidance

Mirion Technologies Inc. reported its financial results for the first quarter of 2024, which ended on March 31st. The company's CEO, Thomas Logan, expressed satisfaction with the results, stating that the revenue growth was in line with their expectations. The strong performance in the Technologies segment contributed significantly to this growth.

Mirion continues to be a global leader in providing radiation detection, measurement, analysis, and monitoring solutions to various industries such as medical, nuclear, defense, and research. The company remains committed to delivering high-quality products and services to its customers.

Looking ahead, Mirion reaffirms its full-year guidance and remai...





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com